T cell engager

Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...

CAMBRIDGE, Mass., July 28, 2026 Cullinan Therapeutics announced positive feedback from the U.S. Food and Drug Administration (FDA) following...

RARITAN, N.J., July 23, 2026 Johnson & Johnson has announced positive topline results from the Phase 3 MonumenTAL-6 clinical...

MIRAMAR, Fla., July 23, 2026 HCW Biologics Inc. announced a significant advancement in the development of its proprietary tetravalent...

PASADENA, Calif., July 17, 2026 Xencor, Inc. announced that Phase 1 clinical results for XmAb819, its investigational ENPP3 ×...

SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...

SAN DIEGO, Calif., July 1, 2026 92Bio, Inc. announced that the first patient has been dosed in its Phase...

SHANGHAI, June 23, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND)...

BOSTON, Singapore and Hong Kong, June 22, 2026 Antengene Corporation Limited has announced a landmark strategic licensing agreement with...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...